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Merozoite invasion of human red blood cells by Plasmodium falciparum is essential for blood stage asexual
replication and the development of malaria disease. Despite this, many of the processes involved in inva-
sion are poorly understood. Recent advances have been made in methods to isolate viable merozoites for
studies of invasion. The application of these approaches is providing new insights into the kinetics of
invasion and merozoite survival, as well as proteins and interactions involved in invasion, and will facil-
itate the development and testing of anti-merozoite vaccines and the identiﬁcation of invasion-inhibitory
compounds with potential for drug development. This review discusses these recent advances and con-
siders potential avenues for future research.
2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Plasmodium falciparum causes the majority of malaria morbidity
and mortality worldwide, with an estimated 781,000 deaths and
225 million cases of malaria annually (World Health Organization
Global Malaria Programme, 2010). Malaria disease occurs during
the asexual blood stage of infection, when the merozoite form of
the parasites invades host red blood cells (RBCs) and establishes
an intracellular trophozoite. The intraerythrocytic parasite grows
and divides over approximately 48 h into a schizont form contain-
ing up to 30 daughter merozoites that are released for subsequent
invasion and replication. Currently there is no vaccine against ma-
laria and with the emergence of resistance to the artemisinin class
of antimalarial drugs (Dondorp et al., 2009), new approaches to
tackling disease are desperately needed. Since the merozoite form
of Plasmodium spp. is extracellular and is exposed to antibodies
and immune cells in the blood stream, merozoite antigens have
long been regarded as attractive targets for vaccine development.
There is also growing interest in the identiﬁcation and develop-
ment of novel drug therapies that target merozoite invasion as
many of the proteins and processes required for invasion are
essential and are unique to the parasite. Despite the importanceInc. Published by Elsevier Ltd.
Medical Research and Public
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Opeof invasion to the P. falciparum life-cycle and malaria disease, our
current understanding of the processes required for merozoite
invasion is far from complete, impeding development and evalua-
tion of vaccines and novel therapeutic compounds. This review will
discuss recent advances in approaches to study merozoite invasion
along with the impact of these methods on our understanding of
merozoite invasion biology, invasion mechanisms and the poten-
tial to apply these methods in the development of vaccines and
new therapeutic compounds.2. Limitations to studying merozoite invasion
Much of our understanding of the basic biology of merozoite
invasion comes from studies completed 20–30 years ago using live
video microscopy (Dvorak et al., 1975) and electron microscopy
(EM) to characterise invasion of merozoites of Plasmodium knowlesi
(Bannister et al., 1975; Aikawa et al., 1978, 1981) and other non-
human Plasmodium spp. (Ladda et al., 1969). From this work it is
clear that merozoite invasion of the RBC progresses through a ser-
ies of coordinated events in a step-wise-like manner. This consists
of initial contact between the merozoite and RBC, reorientation of
the merozoite so that the apical end binds irreversibly to the RBC
surface, formation of tight junction and invasion (reviewed in
Bannister and Dluzewski, 1990) (Fig. 1). Each step in the invasion
process involves a range of receptor–ligand interactions, protein
processing events and signalling cascades. Many merozoiten access under CC BY-NC-ND license. 
Fig. 1. Merozoite invasion of red blood cells. Merozoite invasion appears to occur in a step-wise process. (1) Initial contact occurs between any surface of the free merozoite
and the human red blood cell, with interactions thought to be mediated by merozoite surface proteins; the apical organelles (micronemes and rhoptries) are coloured green.
(2) The merozoite then re-orientates such that the apical end contacts the human red blood cell surface and secondary interactions occur, associated with the release of
proteins from the rhoptries and micronemes, leading to tight junction formation (yellow) between the parasite and the human red blood cell. Re-orientation and tight
junction formation are thought to be mediated by proteins of the apical organelles (micronemes and rhoptries), such as apical membrane antigen 1, erythrocyte binding
antigens and P. falciparum reticulocyte-binding homologues. The release of apical organelles is thought to commence at or immediately following egress, and is completed
after the commencement of invasion. (3) Following tight junction formation the merozoite invades using a unique actin–myosin motor (the moving junction is coloured
blue). (4) Mature invasion is thought to result in the loss of speciﬁc surface proteins and leads to the intraerythrocytic development cycle. Figure adapted from Beeson and
Crabb, (2007).
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2 M.J. Boyle et al. / International Journal for Parasitology 43 (2013) 1–10antigens with potential roles in invasion have been identiﬁed and
localised to the merozoite surface or apical organelles known as
the micronemes, rhoptries and dense granules. However, for most
merozoite proteins a speciﬁc role during invasion is unknown or
poorly deﬁned. Part of this restricted knowledge of invasion events
is due to technical challenges in studying merozoites. Until re-
cently, no well-established or routinely used methods to isolate
P. falciparum merozoites that retained their invasive capacity had
been developed. Consequently, most studies of invasion have
relied on indirect observations of invasion and subsequent blood-
stage development. Alternatively, investigators have used merozo-
ites of other Plasmodium spp. such as P. knowlesi as these have
proven to be more suitable for isolation in vitro. Such studies have
shed light on invasion kinetics (Dennis et al., 1975; Johnson et al.,
1980), speciﬁc protein interactions (Mitchell et al., 2004) and inva-
sion inhibitors (Hadley et al., 1983). However, while P. knowlesi
merozoites are known to have similar invasion kinetics as P. falci-
parum (Dvorak et al., 1975; Gilson and Crabb, 2009), there remains
signiﬁcant differences between the two species in regards to mech-
anisms of invasion, including receptor–ligand use (reviewed in
Gaur et al., 2004).
In P. falciparum, characterization of the role of speciﬁc proteins
during merozoite invasion has been facilitated by the development
of stable genetic transformation technologies, enabling the genera-
tion of modiﬁed parasites with speciﬁc deletions, truncations or
other alterations in key proteins (for example loss or gain-of-
function and tagging (Crabb and Cowman, 1996; Cowman et al.,
2000) and targeting proteins for degradation in conditional
knock-out phenotypes (Meissner et al., 2005; Dvorin et al., 2010)).
Growth defects are typically measured in standard growth inhibi-
tory assays (GIAs), which typically measure total parasite replica-
tion over 48 h (Persson et al., 2006); the assumption is that these
assays mostly assess inhibition or alteration of merozoite invasion.
Differential inhibition of invasion in the presence of vaccine-
induced antibodies and enzyme-treated RBCs with genetically
modiﬁed parasites has helped deﬁne a number of host cell recep-
tor–ligand interactions (for recent reviews on invasionmechanisms
see Farrow et al., 2011; Harvey et al., 2012). However, testing anti-bodies or compounds for activity in standard in vitro GIAs cannot
clearly differentiate merozoite invasion inhibition from potential
inhibitory effects on schizont rupture or merozoite egress and in-
tra-erythrocytic parasite development.
The role of speciﬁc proteins during invasion can further be as-
sessed using standard or advanced microscopy techniques to local-
ise proteins at different stages of the blood stage cycle (Tonkin
et al., 2004; Hanssen et al., 2010a,b; Cho et al., 2012). However,
localisation of proteins during invasion has been hampered by
the inability to isolate sufﬁcient viable merozoites for images of
invasion to be consistently captured (for examples of invading
merozoites captured serendipitously see Langreth et al., 1978;
Baum et al., 2006; Khattab et al., 2008). A more direct way of
studying merozoite invasion is the use of live video microscopy
of merozoite egress and reinvasion (Glushakova et al., 2005,
2010; Gilson and Crabb, 2009; Treeck et al., 2009; Boyle et al.,
2010a; Richard et al., 2010). However, this technique is labour
intensive, typically infers phenotypes or inhibitory activity from
low numbers of events and is not free from the confounding prob-
lem of potential inhibitory effects on the late stage parasite. Limi-
tations on the isolation of viable P. falciparum merozoites has also
made studies of complex and/or low afﬁnity protein interactions,
such as signalling cascades, difﬁcult. As a result, researchers have
frequently turned to studying similar processes in other Apicom-
plexa spp. that are more amenable to these studies (for recent re-
view see Gaur and Chitnis, 2011). Recently signiﬁcant advances
have been made in developing methods to isolate viable P. falcipa-
rum merozoites (Boyle et al., 2010b; Singh et al., 2010). These ap-
proaches have led to new insights into merozoite invasion biology
and the role of speciﬁc proteins during invasion as well as opening
up new avenues of research.
3. New methods to isolate viable merozoites of P. falciparum
Our method to isolate viable merozoites involves the generation
of highly synchronous cultures of mature schizonts at high purity,
followed by puriﬁcation of merozoites using membrane ﬁltration
(for a ﬂow diagram of isolation methods see Fig. 2, detailed meth-
M.J. Boyle et al. / International Journal for Parasitology 43 (2013) 1–10 3ods have been described elsewhere (Boyle et al., 2010b)). An
important aspect of this approach was to develop methods to ob-
tain very tight synchronisation of the developmental stages of P.
falciparum in vitro. This was achieved by ﬁrstly taking advantage
of the speciﬁc invasion-inhibitory activity of heparin (Boyle et al.,
2010a), which can be used to treat cultures for deﬁned periods to
block invasion events and increase the synchronicity of parasite
stages. In addition, we took advantage of the schizont rupture inhi-
bition activity of the cysteine protease inhibitor trans-Epoxysucci-
nyl-L-leucylamido(4-guanidino)butane (E64) which prevents
rupture of the schizont, but does not disrupt merozoite maturationSynchronised parasites, 
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Fig. 2. Methods to isolate Plasmodium falciparum merozoites by membrane ﬁltration. Hig
cells. When developed to segmented schizonts, parasites are treated with trans-Epoxysu
have formed. Merozoites are released by membrane ﬁltration through a 1.2 lm ﬁlte
applications or incubated with uninfected human red blood cells for invasion inhibiti
inhibition assays, merozoites and human red blood cells are incubated in agitated cul
following culture to mature parasites. Hct, haematocrit.or inhibit merozoite invasion (Boyle et al., 2010b). Mature schizo-
nts can then be disrupted by membrane ﬁltration to release and
isolate merozoites. The invasive potential of merozoites is thereby
increased compared with other methods that isolate merozoites
from naturally ruptured schizonts over long time periods during
which time many merozoites lose their invasion potential prior
to being harvested from cultures. Membrane ﬁltration allows for
the isolation of merozoites largely free from intact schizonts, other
parasites stages or uninfected RBCs. Following ﬁltration, merozo-
ites can be incubated with uninfected RBCs allowing for invasion
to proceed. Invasion rates can then be measured immediately bytion 
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hly synchronised trophozoites are magnet puriﬁed to remove uninfected red blood
ccinyl-L-leucylamido(4-guanidino)butane (E64) for 6–10 h until mature merozoites
r. Isolated merozoites can be magnet puriﬁed to remove hemozoin for cellular
on assays. Invading merozoites can be ﬁxed for microscopy studies. For invasion
tures and then either analysed via ﬂow cytometry or microscopy immediately, or
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Wilson et al., 2010, unpublished data), microscopy of ring-stages or
by allowing parasites to develop over 24–48 h in standard culture
conditions and then analysed by ﬂow cytometry (Persson et al.,
2006; Boyle et al., 2010b; Wilson et al., 2010). Potentially, an alter-
native methodology for the staining of ring stage parasites could
also be applied, although the ability to distinguish between true
intraerythrocytic early ring-stage parasites and merozoites bound
to the outside of the RBC requires exploration (Jouin et al., 2004;
Boyle et al., 2010b; Singh et al., 2010; Grimberg, 2011). Invasion
rates of merozoites isolated by this method were estimated at
approximately 15%, which is comparable with standard culture
conditions of 20–40% for the same parasite strain (Boyle et al.,
2010b). Importantly, this invasion efﬁciency was sufﬁcient for
the development of downstream applications such as speciﬁc mer-
ozoite invasion inhibition assays (mero-IIAs) and immunoﬂuores-
cence and EM of invading merozoites (discussed below). Losses
of merozoites occur during the puriﬁcation process and are likely
to result from schizonts being lost during magnet puriﬁcation, loss
of merozoites due to the large volume (300–400 ll) of ﬁltrate
trapped on the ﬁlter membrane, and losses due to schizonts not
ruptured during membrane ﬁltration. Further optimisation may in-
crease isolation efﬁciency, however this isolation method has pro-
ven a robust and efﬁcient approach for a number of different
applications to date.
In contrast, the methods described by Singh et al. (2010) isolate
merozoites following their natural egress from mature schizonts
by differential centrifugation and synchronisation of parasite cul-
tures was achieved using sorbitol. Intact schizonts are then sepa-
rated from released merozoites by centrifugation at 500g, and
merozoites are then harvested from supernatants by centrifugation
at 3,300g. Isolated merozoites were reported to be approximately
25% viable, comparable with naturally released merozoites that
were allowed to invade under standard culture conditions (Singh
et al., 2010). Previously, it has been reported that naturally-
released merozoites that are subsequently isolated by differential
centrifugation are largely non-viable (Blackman, 1994). The suc-
cess of the Singh et al. (2010) method maybe due to a greater level
of synchronisation of parasite cultures that enables schizont rup-
ture and merozoite release in cultures to occur over a shorter per-
iod that leads to better retention of viability; this is also important
for maximising the viability of merozoites obtained using our
membrane ﬁltration approaches (Boyle et al., 2010b). While the re-
ported rate of merozoite viability appears comparable between the
two assays, to the best of our knowledge, no direct comparisons
between the two methods of isolation have been performed. As
our group has no experience in the Singh et al. (2010) method, this
review will focus predominately on insights based on the isolation
of merozoites via membrane ﬁltration methods as described (Boyle
et al., 2010b).4. Insights into invasion biology
4.1. Merozoite survival
Previously, it has been widely accepted that P. falciparum mer-
ozoites have an intrinsically very short viability (minutes or less)
in terms of the ability to invade a new RBC following egress from
the schizont. The invasion process is indeed rapid and can occur
within 1 min of initial contact with the RBC (Gilson and Crabb,
2009). However, until recently, direct evidence for survival of free
merozoites was limited to studies of P. knowlesi merozoites that
have an invasive half-life of approximately 5 min at 37 C (Dennis
et al., 1975; Johnson et al., 1980). It was speculated that the previ-
ous lack of success in isolating viable P. falciparum merozoites wasa consequence of the half-life of P. falciparum being shorter than P.
knowlesi spp. This concept has inﬂuenced other ideas surrounding
invasion and immunity. For example, it was proposed that invasion
inhibitory antibodies would require high concentrations to effec-
tively block invasion due to rapid invasion kinetics (Saul, 1987)
and the potential impact of cell-mediated immune mechanisms
such as phagocytosis may be limited due to the small opportunity
for phagocytosis to occur before a merozoite invades or becomes
non-viable.
Using merozoites isolated via membrane ﬁltration, the half-life
of merozoites following release from schizonts was deﬁned (Boyle
et al., 2010b). Measurements of the time until invasion occurs after
mixing merozoites with RBCs and the loss of invasive potential of
merozoites when they are incubated for deﬁned periods in the ab-
sence of RBCs suggest that the invasive half-life was approximately
8 min at 37 C. This is substantially longer than previously pro-
posed. Furthermore, it should be noted that a proportion of mer-
ozoites remained invasive for much longer periods of time, with
20% of invasion events occurring more than 10 min after contact
with RBCs and invasion rates of up to 20% observed when merozo-
ites were incubated for 10 min in the absence of RBCs prior to test-
ing for invasive potential. Investigating the effect of temperature
on the invasive half-life of merozoites resulted in a pattern of via-
bility very similar to that previously reported for isolated P. knowl-
esi merozoites, with similar survival when merozoites were
incubated on ice or at 37 C and increased survival, with a half-life
of approximately 20 min, when incubated at room temperature
(Johnson et al., 1980; Boyle et al., 2010b).
It is hypothesised that the loss of invasiveness of merozoites
may be due to aberrant triggering of invasion events such as the
spontaneous cleavage and/or shedding of surface proteins, such
as merozoite surface protein 1 (MSP1), which can occur in the ab-
sence of invasion (Langreth et al., 1978; Johnson et al., 1981;
Blackman et al., 1991); premature release of rhoptry and micro-
neme organelle proteins so that merozoites can no longer attach
to RBCs (Johnson et al., 1980); or loss of metabolic activity. Our
ﬁnding that a signiﬁcant proportion of merozoites remain invasive
for longer time periods has a number of implications for our under-
standing of merozoite invasion biology. Firstly, these data suggest
that merozoites are not intrinsically short lived and may not be
programmed to ‘invade’ immediately after egress from the schiz-
ont and instead need an additional signal to trigger invasion. This
concept is supported by the observation that a proportion of mer-
ozoites maintain viability for long time periods in the absence of
RBCs (>10 min). The ability of merozoites to maintain viability
while inside E64-treated schizonts and then lose viability after
membrane ﬁltration supports the hypothesis that the trigger for
invasion is an environmental change, such as the release of micro-
neme proteins triggered by low potassium concentrations (Singh
et al., 2010). However, it is also possible that microneme release
is not directly linked to subsequent cascades of invasion steps,
which may require other triggers such as contact with the RBC to
commit to invasion (Riglar et al., 2011). Indeed, if the change in
potassium levels was triggering the loss of viability due to micro-
neme release, one would expect that this process would be uni-
form in all merozoites in the preparations used for these studies.
In contrast, there is clearly a proportion of merozoites surviving
for extended periods of time, suggesting that multiple mechanisms
are at play in loss of viability.
The increased invasive half-life when kept at room temperature
compared with 37 C suggests that mechanisms such as metabo-
lism or enzyme function resulting in cleavage and/or shedding of
merozoite antigens involved in the invasion process may contrib-
ute to loss of viability. However, in preliminary experiments there
is no evidence for the spontaneous shedding and loss of surface
proteins over time, with similar proportions of isolated merozoites
M.J. Boyle et al. / International Journal for Parasitology 43 (2013) 1–10 5labelled with MSP1-block two antibodies at 1–2 h post isolation,
compared with immediately following ﬁltration (M. Boyle, D. Wil-
son, J. Beeson, unpublished data). Interestingly, when merozoites
were incubated at 40 C prior to addition of RBCs to mimic febrile
illness, a dramatic loss of invasiveness was seen compared with
37 C (Boyle et al., 2010b). Febrile temperatures are known to inhi-
bit intra-erythrocytic development of late stage parasites
(Kwiatkowski, 1989; Long et al., 2001), however, the effect of fever
on merozoite invasion per se is unknown. The loss of viability of
merozoites when incubated at 40 C may indicate that fever could
be beneﬁcial for malaria patients by reducing merozoite invasive
capacity. The beneﬁt of fever in malaria illness has been suggested
previously, with increased parasite clearance times observed for
patients treated with antipyretics (Brandts et al., 1997).
4.2. Implications of merozoite survival times on immune mechanisms
and inhibition of invasion
It is difﬁcult to extrapolate the estimated half-life of P. falcipa-
rum merozoites in vitro to the situation in vivo due to the chal-
lenges of reproducing normal physiological conditions in the
laboratory, and the limitations in our knowledge of human infec-
tion. Indeed, currently there is no experimental evidence to inform
our understanding of how long merozoites are extracellular and
viable within the circulation or knowledge of the time over which
invasion occurs in vivo. Late stage parasites are able to sequester in
various microvascular beds and this process may result in seques-
tered schizonts undergoing rupture and release of merozoites in
areas where blood ﬂow is reduced (Dondorp, 2008), and where
there are few RBCs for invasion by merozoites. It is interesting to
speculate that under these conditions a longer invasive half-life
may be advantageous to enable the merozoite to migrate to a cap-
illary or small blood vessel containing uninfected RBCs receptive to
invasion. Equally, it can also be hypothesised that when schizont
rupture occurs in the blood-stream in vivo, merozoites might have
ready access to a large number of uninfected RBCs. This could re-
sult in rapid invasion and there would be no need for merozoites
to have extended viability. Further studies to understand these
possibilities and the relevance of merozoite viability over time
are needed.
From an immunological perspective, the longer than expected
survival of merozoites may have important implications for our
understanding of immunity to malaria. Approximately 5% of the
blood volume circulates through the spleen every minute, and con-
sequently it is likely that viable and intact merozoites would be
captured by the spleen, which is thought to be able to trap particles
greater than 200 nm in size (Moghimi et al., 1993; Champion et al.,
2007). Correctly presented merozoite antigens would thus be ex-
posed to splenic immune cells for phagocytosis, antigen presenta-
tion and activation of the immune system. Furthermore, if invasion
occurs over several minutes, antibodies would have a much longer
time to coat merozoites and block invasion than was previously
estimated (Saul, 1987), and cellular immune responses such as
phagocytic uptake of merozoites may play an important role, as
previously proposed (Bouharoun-Tayoun et al., 1990). Based on
the model by Saul (1987), if merozoites come into contact with
RBCs and are able to invade within 1–2 min post egress, then high-
er concentrations of antibodies would be required to inhibit inva-
sion (estimated at P10 lg/ml). While antibodies with invasion
inhibitory activity against important invasion ligands, such as api-
cal membrane antigen 1 (AMA1), have been reported at high en-
ough concentrations to meet this theoretical level for vaccinated
unexposed individuals (Duncan et al., 2011), naturally exposed
children (Thera et al., 2011) and adults (Hodder et al., 2001), it is
possible that lower concentrations of antibody are also inhibitory.
Future studies are needed to better understand the in vivo kineticsof merozoite-RBC interactions and the implications of these kinet-
ics on both vaccine-induced and naturally-acquired immune
responses.
4.3. The role of serum components and complement in invasion
Serum components, such as complement, are important con-
tributors to innate immunity and have roles in inhibiting pathogen
replication. However, many infectious organisms co-opt serum
components to facilitate infection. Using conventional growth as-
says, it has been previously shown that parasite replication
in vitro does not require human serum components (many groups
routinely culture parasites using AlbumaxII supplemented med-
ium and not human serum). However, these assays can only mea-
sure serum at 10–20% concentrations, well below physiological
concentrations, and have not speciﬁcally assessed the involvement
of serum components for invasion. Utilising isolated merozoites in
mero-IIAs, it was observed that merozoite invasion occurred efﬁ-
ciently in the presence or absence of serum; at high serum concen-
trations invasion occurred efﬁciently, but was slightly reduced
compared with serum-free conditions (Boyle et al., 2010b). Subse-
quent experiments have shown that complement does not appear
to inhibit or enhance merozoite invasion, with comparable levels
of invasion observed in heat-inactivated and normal human serum
(at concentrations up to 80%) (M. Boyle, J. Beeson, unpublished
data). Together these ﬁndings suggest that host serum components
are not important in merozoite invasion. Of note, an interaction be-
tween the merozoite protein reticulocyte binding homologue 4
(Rh4) and human complement receptor 1 (CR1) on the RBC surface
has been implicated in invasion via the sialic-acid independent
pathway (Spadafora et al., 2010; Tham et al., 2010). Additionally,
a complex between CR1, Rh4 and the serum complement compo-
nent C4b has recently been described (Tham et al., 2011). It has
been proposed that this tertiary structure may be beneﬁcial to
the parasite by enhancing the afﬁnity of the Rh4–CR1 interaction
(Tham et al., 2011) presumably resulting in higher invasion efﬁ-
ciency. If CR1/Rh4 pathway was enhanced by binding C4b, it would
be expected that higher invasion would be observed in normal ser-
um compared with heat-inactivated serum, which lacks active
complement. Previously published data showed that the addition
of C4b or C3b to standard GIA did not enhance or disrupt invasion
(Tham et al., 2011). This suggests that complement components
are not involved in enhancing merozoite invasion.
4.4. Insights into mechanisms of invasion with microscopy studies
Using isolated invasive merozoites, methods were developed to
ﬁx merozoites during invasion for microscopy studies. Previously,
EM imaging of merozoite invasion has been limited to other Plas-
modium spp. such as P. knowlesi. To the best of our knowledge,
there had only been one previously reported EM of P. falciparum
invading merozoites that was captured serendipitously (Langreth
et al., 1978). With isolated viable merozoites, ﬁxation of invading
merozoites can be consistently achieved, allowing for in-depth
investigation and localisation of proteins in both immunoﬂuores-
cence and EM studies (Fig. 3). Although these imaging techniques
only capture merozoites invading at single snap-shots in time (as
opposed to single cell time-lapse microscopy), and therefore may
not entirely reﬂect the true sequence of events, this technique
has none-the-less led to a number of important insights into spe-
ciﬁc mechanisms of invasion; the conﬁrmation that commitment
to invasion occurs after attachment of the merozoite to RBCs and
formation of the tight junction, triggering subsequent events of
rhoptry secretion, surface-protein shedding and actin–myosin mo-
tor activation (Riglar et al., 2011). The proposed shedding of the
major surface protein MSP1 at the tight junction between the
Fig. 3. Imaging of merozoites during invasion. Isolated merozoites are able to be
ﬁxed during invasion for microscopy studies. Here, merozoites were ﬁxed during
invasion and labelled with antibodies to Plasmodium falciparum rhoptry neck
protein (PfRON)4 (green) and merozoite surface protein (MSP)1-83 kDa fragment
(red). PfRON4 effectively marked the point of invasion between the merozoite and
red blood cell allowing for analysis of surface protein shedding. MSP1-83 was shed
at the point of tight junction between the merozoite and human red blood cell.
Preparation and staining of cells was performed as described (Boyle et al., 2010b).
Antibodies for labelling were kindly provided by D. Conway and K. Tetteh (MSP1-
83) and A. Cowman (RON4).
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Riglar et al., 2011), as shown previously with P. knowlesi (Blackman
et al., 1996). The mechanisms mediating MSP1 shedding now re-
quire further study; shedding is known to occur with the cleavage
of MSP1-42 to MSP1-33 and MSP1-19, mediated by the by subtil-
isin protease, PfSUB2 (Harris et al., 2005). However, the localization
of PfSUB2 during invasion appears different from the point of shed-
ding with PfSUB2 tracking to the posterior of the invading merozo-
ite before MSP1 shedding occurs (Riglar et al., 2011). Furthermore,
it has been proposed by the earliest EM images of invading Plasmo-
dium merozoites that all merozoite surface proteins are shed dur-
ing invasion, with a complete loss of surface coat on the merozoite
after the point of tight junction with the RBC (Bannister et al.,
1975; Aikawa et al., 1978, 1981). However, while this shedding
has been clearly shown for MSP1, direct evidence for the loss of
other surface proteins during invasion is currently lacking. Our
ongoing studies suggest that cleavage and shedding of surface pro-
teins is not universal, but instead is selective to speciﬁc proteins
(M. Boyle, J. Beeson, unpublished data). While it is thought that
surface proteins are involved in mediating initial contact steps be-
tween the merozoite and the RBC, there are limited data to support
the role of surface proteins directly in initial contact. To the best of
our knowledge only one RBC receptor has been reported for a mer-
ozoite surface protein, with MSP1-19 reported to bind Band3
(Goel et al., 2003). Other studies suggest that MSP1-42, but not
the full-length unprocessed form of MSP1, may bind heparin-like
molecules on the RBC (Boyle et al., 2010a). The characterization
of surface protein localisation during invasion may shed light on
to the potential multiple functions of surface proteins during inva-
sion and downstream of invasion.
Further application of these methods in merozoite isolation and
microscopy have enabled the localisation of a number of merozoite
proteins involved in invasion, including rhoptry and motor com-
plex associated proteins (Chen et al., 2011; Triglia et al., 2011;
Wong et al., 2011; Angrisano et al., 2012). In other studies, isolated
merozoites have been used for the investigation of cellular im-
mune responses (Costa et al., 2011), with the ability to remove
contaminating hemozoin crystals from ﬁltrates allowing the appli-
cation of isolated merozoites to other cellular assays (Boyle et al.,
2010b). In addition, isolation of viable merozoites using differential
sedimentation techniques has shed light on the triggers and
signalling pathways involved in invasion (Singh et al., 2010). The
development of methods to isolate viable merozoites has therefore
opened new avenues to study a range of aspects of merozoite
invasion biology and immune mechanisms targeting merozoite
stages.5. Drug and vaccine development
5.1. Development of speciﬁc invasion inhibition assays
Prior to the development of a robust method for puriﬁcation of
invasive P. falciparummerozoites, in vitro studies looking at poten-
tial invasion inhibitory activity of antibodies and compounds for
vaccine and drug development have relied on measuring inhibition
of total blood-stage replication of parasites, rather than inhibition
of invasion. This approach has the obvious disadvantage that any
inhibitory activity measured could also result from inhibition of
late stage parasite development, schizont rupture and/or growth
of the newly invaded ring-stage parasite. The development of reli-
able methods to isolate viable P. falciparum merozoites with high
yield has now allowed for the study of invasion inhibitors speciﬁ-
cally (Boyle et al., 2010b).
As a proof of principle during the initial assessment of mero-
IIAs, the activity of known invasion inhibitors was conﬁrmed; this
included heparin (inhibits initial attachment of the merozoite to
RBC), AMA1 targeting peptide R1 and monoclonal antibody 1F9
(which inhibit the formation of the tight junction), and actin inhib-
itor cytochalasin D (inhibits gliding motility and merozoite pene-
tration of the RBC). Comparison of the inhibitory activity of the
cysteine protease inhibitor E64 and the serine/cysteine protease
inhibitor N-a-Tosyl-L-lysine chloromethyl ketone (TLCK) also high-
lighted the value of mero-IIAs; while E64 is inhibitory to schizont
rupture, it has no inhibitory activity against merozoite invasion,
suggesting that cysteine proteases may have a limited role in mer-
ozoite invasion. In contrast, the serine/cysteine protease inhibitor
TLCK was inhibitory to both invasion and rupture (Boyle et al.,
2010b), as has been shown for P. knowlesi (Hadley et al., 1983), sug-
gesting that serine proteases may play an important role in
invasion.
In the case of the AMA1 inhibitors R1 and 1F9 (Boyle et al.,
2010b), as well as heparin (M. Boyle, D. Wilson, J. Beeson, unpub-
lished data), mero-IIAs were more sensitive than GIAs for measur-
ing inhibitory activity. While the reasons for greater sensitivity in
mero-IIA were not explored, it is possible that degradation of
inhibitory compounds occurs in GIAs (typically conducted over
48–72 h incubation) compared with mero-IIAs where the com-
pound is added immediately prior to invasion. It is also possible
that differences in haematocrit and merozoite: RBC ratios between
the two assays may affect inhibition activity, a phenomenon which
has been suggested in previous reports on inhibitory antibodies
(Saul et al., 1982); however, these factors have not been found to
have a major effect in other studies by our group (Persson et al.,
2006; Wilson et al., 2010). Although mero-IIAs were more sensitive
and speciﬁc than GIAs, at present it is not known which assay is
likely to be more relevant to the activity of compounds or antibod-
ies in vivo. Indeed, compounds that function on inhibiting intra-
erythrocytic development, or targeting processes upstream of
invasion such as merozoite protein maturation, are more appropri-
ately tested in GIA.5.2. Inhibitors of invasion as novel therapeutic agents
Currently, all licensed malaria therapeutic agents target the in-
tra-erythrocytic development of the parasite. Merozoite invasion,
as a key point in parasite development, may also have potential
for intervention with targeting of proteases or essential proteins,
as discussed previously (O’Donnell and Blackman, 2005;
Wegscheid-Gerlach et al., 2010; Macraild et al., 2011). There may
be potential for the use of merozoite invasion inhibitory drugs in
combination with drugs targeting the intra-erythrocytic develop-
ment. Combination treatments targeting different stages may
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decrease the emergence of drug resistance. Our ongoing studies
of antimalarial drug activity suggest that none of the antimalarial
agents in widespread use have activity against merozoite invasion
(D. Wilson, J. Beeson, unpublished data).
Polysulphated heparin-like-molecules (HLMs) are inhibitory to
invasion (Boyle et al., 2010a) and may have potential as antimalar-
ial agents (Havlik et al.,1994, 2005; Clark et al., 1997; Evans et al.,
1998; Adams et al., 2006; Boyle et al., 2010a). From testing a num-
ber of modiﬁed HLMs and semi-synthetic carbohydrates based on
K5 polysaccharides that have different compositions, it has been
previously shown that the invasion-inhibitory activity of these
compounds is speciﬁc and dependent on the level and degree of
sulphation, as well as backbone structure and chain length (Boyle
et al., 2010a). The activity of these compounds appears to result
from their ability to bind to MSP1-42 (Boyle et al., 2010a), but they
may bind other proteins involved in invasion (Baum et al., 2009;
Kobayashi et al., 2010). In human malaria, heparin has previously
been used to treat disseminated intravascular coagulation
(Smitskamp and Wolthuis, 1971; Mitchell et al., 1974; Munir
et al., 1980; Rampengan, 1991). However, due to the high risk of
bleeding resulting from anticoagulant activity, heparin treatment
is no longer recommended (World Health Organization, 2010).
Our studies and others suggest it is possible to reduce or remove
the anticoagulant activity of HLMs while maintaining inhibitory
activity against P. falciparum (Vogt et al., 2006; Boyle et al.,
2010a). Indeed, periodate-treated HLMs have been identiﬁed that
have no anticoagulation activity nor toxicity in heart, liver, kidney
or lung tissue (Yu et al., 2010) and shown to have activity in a mur-
ine model (Vogt et al., 2006). Furthermore, the polysaccharide
curdlan sulphate has been tested in a small Phase IIB human trial
which suggested that treatment reduced malaria disease severity
(Havlik et al., 2005). Curdlan sulphate inhibits invasion, but also
has broader biological activities that may contribute to its activity.
It is possible that in the future oligosaccharide HLM compounds
with increased bioavailability/kinetics/safety and improved inhib-
itory activity may be developed.
The potential for the development of antimalarial drugs target-
ing merozoite invasion is not limited to HLMs. A number of poten-
tial drug targets have been identiﬁed such as proteases and kinases
that have essential roles in processes such as protein cleavage,
rhoptry and microneme release, signalling and activation of the
invasion motor. Further, new libraries of drugs with antimalarial
properties have recently been provided to the research community
for further drug research development (Gamo et al., 2010;
Guiguemde et al., 2010), some of which may have inhibitory activ-
ity against merozoite invasion.
5.3. Vaccines and immunity
The importance of humoral responses against blood stages has
been well demonstrated, with studies showing that immunoglob-
ulin from immune adults can be transferred to infected children,
resulting in recovery and parasite clearance (McGregor, 1964;
Sabchareon et al., 1991). However, the mechanisms mediating pro-
tective immunity are unclear as correlates of protection remain
poorly characterised with respect to both the mechanisms and tar-
gets of immunity. Antibodies targeting merozoites surface antigens
and invasion ligands are thought to contribute to immunity
(Richards and Beeson, 2009; Fowkes et al., 2010). Assays that are
currently used to measure functional antibodies to merozoite anti-
gens include GIAs, antibody dependent cellular inhibition assays
(ADCI), and neutrophil respiratory burst (Bouharoun-Tayoun and
Druilhe, 1992; Persson et al., 2006; Joos et al., 2010). GIAs typically
measure the ability of total or dialysed serum, or puriﬁed
serum IgG, to inhibit growth of parasites over one or two cyclesof replication in in vitro, with parasitemia measured by micros-
copy, ﬂow cytometry or other methods (O’Donnell et al., 2001;
Kennedy et al., 2002; Bergmann-Leitner et al., 2006; Persson
et al., 2006, 2008; McCallum et al., 2008; Wilson et al., 2010,
2011). These assays are often reported to be a measure of ‘invasion
inhibitory’ activity; however, as discussed earlier, the nature of the
assay means that inhibitory effects measured may be due to
activity distinct from direct merozoite invasion inhibition, such
as inhibition of intra-erythrocytic growth, schizont rupture and/
or merozoite dispersal.
Signiﬁcant efforts by multiple laboratories has been undertaken
to increase the validity and throughput of GIAs by increasing accu-
racy of parasitemia measurements using ﬂow cytometry (com-
pared with microscopy), using dialyzed serum samples to
remove inhibitory drugs, comparing multiple GIA techniques, test-
ing serum against drug-resistant lines or by the use of puriﬁed IgG
(Kennedy et al., 2002; Persson et al., 2006; Bergmann-Leitner et al.,
2008; Dent et al., 2008; Wilson et al., 2010). However, despite the
best efforts, the validity of GIA as a measure of protective immune
function remains unclear. Investigators have reported either no
associations between GIA and protection from malaria (Marsh
et al., 1989; McCallum et al., 2008) or only weak associations (John
et al., 2004; Dent et al., 2008; Crompton et al., 2010). Furthermore,
some investigators have reported growth enhancement by some
puriﬁed IgG samples (Shi et al., 1999). This does not necessarily
suggest that growth inhibition of P. falciparum is not important
in protective immunity, but may indeed reﬂect the limitations of
GIAs to detect activity due to assay limitation or that GIA is only
one component mediating protection. In the testing of antibodies
in serum, GIAs are limited to 1:10 or 1:5 serum dilutions as high
serum concentrations in vitro causes non-speciﬁc inhibition. Con-
sequently, concentrations of antibodies in GIA may be below the
threshold for the detection of growth inhibition activity (Wilson
et al., 2011). While others have used puriﬁed IgG at higher concen-
trations, GIAs are further limited as they do not account for the
possibility of antibodies interacting with complement factors as
most studies have tested serum after heat inactivation (which dis-
rupts complement function) or have used puriﬁed IgG. The devel-
opment of a speciﬁc mero-IIA with isolated viable merozoites may
overcome some of these limitations of standard GIA. Our labora-
tory is now applying mero-IIA to the study of mechanism of anti-
body targeting merozoite invasion speciﬁcally. In ongoing
studies, we have established that some individuals in malaria-
endemic areas have antibodies that can directly inhibit invasion,
but the relative importance of these antibodies in protective
immunity remains to be established (M. Boyle, J. Beeson, unpub-
lished data).6. Future directions
The continuing high burden of malaria globally is a sobering re-
minder of the urgent need for vaccines and new therapeutic agents
for malaria prevention and treatment. Merozoite invasion of RBCs
is an attractive target for both vaccine and drug development,
highlighting the importance of further studies to understand the
mechanisms and interactions involved in invasion, and to identify
and evaluate candidate anti-merozoite vaccines and invasion-
inhibitory compounds. New methods to isolate viable merozoites
provide an important tool for studies of invasion and invasion
inhibitors, as described in this review. These methods have many
potential further applications, such as proteomics, metabolomics,
and transcriptional analyses. Furthermore, it may be possible to
use isolated merozoites for transfection to obtain higher transfec-
tion efﬁciencies, as is done with Plasmodium berghei (van Dijk
et al., 1995). Further advances to the methods described recently
8 M.J. Boyle et al. / International Journal for Parasitology 43 (2013) 1–10(Boyle et al., 2010b; Singh et al., 2010) could lead to major new in-
sights that enhance our understanding of the process of P. falcipa-
rummerozoite invasion, the most ﬂeeting stage of the intracellular
parasite lifecycle.
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